Qyuns Therapeutics Co Ltd

Qyuns Therapeutics Co., Ltd. is a clinical-stage biotechnology company focused on researching and developing biologic therapies for autoimmune and allergic diseases in China. Its lead candidates include QX002N, an IL-17A inhibitor that completed Phase III trials for ankylosing spondylitis, and QX005N, an IL-4Rα-blocking monoclonal antibody in Phase III for prurigo nodularis. The company also develops QX001S (an IL-12/L-23p40 inhibitor for psoriasis under the SAILEXIN brand), QX008N (a humanized IgG1 mAb targeting TSLP in Phase Ib for moderate-to-severe asthma and COPD), and QX004N (an IL-23p19 inhibitor in Phase II for psoriasis and Crohn's disease). Additional pipeline assets include QX027N, QX030N, QX031N, and QX035N. Incorporated in 2015, Qyuns Therapeutics is headquartered in Taizhou, China, and also manufactures and sells pharmaceutical products and provides technical consultation services.